🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Global Public Health Issue

Gonorrhoea infections are escalating worldwide, with figures suggesting in excess of 82 million new cases annually. Notably increased rates are observed in the African continent and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the reality of growing infection rates, escalating drug resistance and the very limited therapeutic options currently available.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Receive Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the US FDA in December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts hope that specific application of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a unique collaborative effort for drug creation. The non-profit organisation GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Results and Global Access

Based on data detailed in a prominent scientific publication, the new drug eradicated over nine in ten of cases of the STI. This establishes an similar efficacy with the typical regimen, which involves an injection and a pill. The trial enrolled hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to register and commercialise the drug in many developing nations.

Medical professionals treating patients have shared optimism. Access to a one-pill regimen of this kind is hailed as a "critical tool" for managing the epidemic. This is viewed as essential to alleviate the strain of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea worldwide.